Cocrystal Pharma Inc. Announces Phase 1 Study Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference
I'm PortAI, I can summarize articles.
Cocrystal Pharma Inc. announced positive Phase 1 study results for its pan-viral inhibitor CDI-988, presented at the 2025 Military Health System Research Symposium. The randomized, double-blinded, placebo-controlled study showed that all doses (100 mg to 1200 mg) were well tolerated. CDI-988 aims to treat norovirus, addressing a significant medical need. A Phase 1b study with norovirus-infected healthy subjects is planned for later this year. The development is supported by Cocrystal’s structure-based platform technology for broad-spectrum antivirals.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments